Happy Autumn to all! As we head into CPHI Frankfurt next week, our commercial team and technical subject matter experts anticipate many fruitful discussions across our six technology platforms. At the top of the agenda, is reiterating the value CordenPharma places on supporting you as a true CDMO partner. One of the ways we deliver that is to anticipate pharmaceutical market modalities by connecting past achievements with future needs.
As a patient and customer-centric organization, CordenPharma follows the rise and extension of modalities very closely. Foremost, the innovative power and dedication of the pharmaceutical community to go even further with better treatment options serves as everyday motivation to support innovators with development and manufacturing solutions that match their ingenuity and scientific excellence.
Across our 6 distinctive technology platforms, CordenPharma provides true end-to-end support that helps customers reach critical milestones across all three modality types – Mature, Advancing, and Emerging:
(Graphic by CordenPharma) – CordenPharma technology platforms supporting both drug substance and drug product across mature, advancing and emerging modalities.
Mature modalities like classical small molecules, monoclonal antibodies or proteins (recombinant as well as manufactured with classical chemical methods) are – when measured in worldwide sales – still leading and will continue to do so. Looking at projected sales in 2029 we believe the top 10 successful programs will be comprised by proteins (recombinant or chemical), monoclonal antibodies and conventional small molecule drugs.
From Drug Substance manufacturing of conventional small molecule drugs to chemically synthesized peptides, we extend value to customers through integrated downstream services via our Oral Solid Dose (OSD) and sterile injectable aseptic fill and finish Drug Product operations; all 10 of our production sites in North America and Europe support those mature modalities.
Another indicator for the innovative drive across the industry is the number of pipeline compounds currently active, particularly for the segment of advancing or emerging modalities. Not surprisingly the monoclonal antibodies (~2.700 compounds in various stages of development, according to our market intelligence department) and peptides (2.100 compounds) are leading in numbers, but the advancing modalities also demonstrate a strong interest with Drug Conjugates (700 compounds) and Gene Therapies (800 compounds) leading this group. Here, CordenPharma excels as your partner of choice in advancing modalities with specialized expertise across our Peptides, Lipids & LNPs, Injectables, and Highly Potent & Oncology technology platforms.
When looking towards emerging modalities today we find roughly 177 total active compounds across the mRNA space, most of which are focused on oncology and continued respiratory pathogens. Based on these numbers, the value of CordenPharma’s multiple technology platform strategy from mRNA to peptides becomes very clear: for nearly 40 years we have been active in the field of specialized lipids and continue to improve our manufacturing strategies for those compounds. With the immediate market need to step up lipid supply during the COVID pandemic, CordenPharma demonstrated we had the knowledge, experience and dedicated teams needed to upscale the manufacturing of lipids from gram to tons within a short time, activating 4 of our small molecule drugs substance manufacturing sites.
The same holds true with peptides, produced using the SSPS manufacturing concept. Prior to the ever-increasing rise in supply demand for the anti-obesity GLP-1 market, CordenPharma already had decades of proven experience and knowledge to operate peptide manufacturing facilities utilizing 10.000 L SSPS trains. So now, our position as peptide leaders means we can readily support innovators with scaling up peptide production from kg to now multiple ton quantities.
In parallel, our CDMO strategy incorporates continuous investigations into scientific depth. For years the scientists in our innovation department have been working on ways to increase the bioavailability of drug development to support your Oral Solid Dose (OSD) Drug Product needs. Now they are applying all their knowledge to help you advance in the field of oral peptide delivery, especially for the anti-obesity indications.
As a leading CDMO we strive to react nimbly to the challenges new modalities create, and help you, our customers, to bring much needed life-changing medication to patients in need. While we continue to add more knowledge and experience, bolstered by extensive investments across all technology platforms, we are proud of our recently AIFA-approved GMP LNP manufacturing suite as an important capacity for today’s emerging modalities. When it comes to PROTAC (proteolysis-targeting chimera). we again employ all our platform knowledge to help strengthen this sector.
CordenPharma is the partner you need for mature, advanced or emerging modalities, for all manufacturing scales and scientific challenges across your drug lifecycle.
I hope you enjoy the Q3 2025 newsletter covering:
On 9 September we held our inaugural LNP Summit in Boston – the event was a true success! Here’s a video summarizing the summit speakers and their topics – which fostered a lot of exchange about the challenges and important innovations powering the future of nanomedicines.
We look forward to meeting existing and new customers at the upcoming Fall trade shows! To schedule an appointment, Contact us today:
On behalf of the whole CordenPharma team, we are very grateful to work with you, our valued and loyal customers, in bringing innovation and medication to patients.
Dr. Stephan Haitz
Chief Commercial Officer
CordenPharma
